ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer - Concepedia

Concepedia

Publication | Open Access

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

DOI Full Paper Access

83

Citations

35

References

2000

Year

Olle Stål, Åke Borg, Mårten Fernö, Ann-Christine Källström, Bo Nordenskjöld

Annals of Oncology

Breast OncologyOncologyMedicineGynecologyAdjuvant TamoxifenBreast CancerCancer TreatmentPharmacologyEndocrine-related CancerErbb2 Status

References

	Year	Citations

Page 1